Watch Dr. William Wierda discuss how CAR T-cell therapy works as well as side effects caused by this cancer treatment.
MD Anderson’s patient-centric approach to research is advancing the understanding of malignant and non-malignant blood disorders and extending patients’ lives.
At the ASH Annual Meeting and Exposition, our experts showcased their practice-changing work with colleagues from across the globe for large-scale discussion.
Below is a snapshot of the work our experts presented at the 2019 meeting, as well as more about our pioneering hematology research. Bookmark this page for updates about next year’s meeting and beyond.
Lower-dose chemotherapy plus monoclonal antibodies is highly effective for older patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia.
Enasidenib plus azaticidine significantly improves complete remission and overall response for patients with acute myeloid leukemia tied to IDH2 mutations.
One-year Phase II study results show the majority of mantle cell lymphoma patients who relapsed achieved complete response thanks to CAR T-cell therapy.
Saturday, Dec. 7
Emerging themes in T-cell lymphoma: Nodal and cutaneous
Conferences and Educational Events
View a list of professional, CME-accredited conferences and educational events.
Moon Shots Program
Our intentions are noble – put blood cancers at the forefront of our investigation to make their cure a future reality. Our process is groundbreaking – use in-house, industry-quality platforms to ensure that our breakthrough discoveries aren’t left sitting in research labs.
By combining Innovation, Collaboration and Scale, the Moon Shots Program® is revolutionizing the conventional medical research approach to rapidly adapt pre-clinical findings into treatment options for challenging blood cancers.